Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes:results from the Collaborative Atorvastatin Diabetes Study (CARDS)

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Colhoun, H
Betteridge, D
Durrington, P
Hitman, G
Neil, H
Livingstone, S
Thomason, M
Mackness, M
Charlton-Menys, V
Fuller, J

January 2004

BACKGROUND: Type 2 diabetes is associated with a substantially increased risk of cardiovascular dise...

Statins for cardiovascular prevention according to different strategies: a cost analysis

Ito, Marcia K
Nanchen, David
Rodondi, Nicolas
Paccaud, Fred
Waeber, Gérard
Vollenweider, Peter
Marques-Vidal, Pedro

January 2011

Several studies have shown that treatment with HMG-CoA reductase inhibitors (statins) can reduce cor...

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).

Knopp, Robert H
d'Emden, Michael
Smilde, Johan G
Pocock, Stuart J

January 2006

OBJECTIVE: Cardiovascular disease (CVD) risk is increased in type 2 diabetes. The purpose of this st...

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes:results from the Collaborative Atorvastatin Diabetes Study (CARDS)

Raikou, M
McGuire, A
Colhoun, H M
Betteridge, D J
Durrington, P N
Hitman, G A
Neil, H A W
Livingstone, S J
Charlton-Menys, V
Fuller, J H

January 2007

We estimated the cost-effectiveness of atorvastatin treatment in the primary prevention of cardiovas...

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).

Raikou, M
McGuire, A
Colhoun, HM
Betteridge, DJ
Durrington, PN
Hitman, GA
Neil, HA
Livingstone, SJ
Charlton-Menys, V
Fuller, JH

April 2007

AIMS/HYPOTHESIS: We estimated the cost-effectiveness of atorvastatin treatment in the primary preven...

Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: A French adaptation of CARDS

Lafuma, Antoine
Colin, Xavier
Solesse, Anne

May 2008

SummaryIntroductionWe estimated the cost-effectiveness of atorvastatin in the primary prevention of ...

Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative Atorvastatin diabetes study in the Belgian population

Annemans, Lieven
Marbaix, S
Webb, K
Van Gaal, Luc
Scheen, A

January 2010

Background and Objective: Patients with type 2 diabetes mellitus have a high risk of developing card...

Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.

Annemans, L.
Marbaix, S.
Webb, K.
Van Gaal, L.
Scheen, André

January 2010

BACKGROUND AND OBJECTIVE: Patients with type 2 diabetes mellitus have a high risk of developing card...

CANADIAN JOURNAL OF DIABETES. 2009;33(4):363-374. COST-EFFECTIVENESS OF ATORVASTATIN IN DIABETES | 363

August 2015

OBJECTIvE: To assess the clinical and economic benefits of atorvastatin for Canadian patients with t...

Economic evaluation of the CARDS study

Lorenzo G. Mantovani
Simona de Portu
Enrica Menditto

September 2006

Introduction: cardiovascular diseases (CVD) are the major component of premature mortality, generate...

Cost-effectiveness of statins for primary prevention in newly diagnosed type 2 diabetes patients: An illustration for The Netherlands

De Vries, Folgerdiena M.
Denig, Petra
Visser, Sipke T.
Hak, Eelko
Postma, Maarten J.

October 2013

Background: Patients with type 2 diabetes have an increased risk of cardiovascular events, which can...

Cost-effectiveness of statins for primary prevention in newly diagnosed type 2 diabetes patients:An illustration for The Netherlands

De Vries, Folgerdiena M.
Denig, Petra
Visser, Sipke T.
Hak, Eelko
Postma, Maarten J.

October 2013

Background: Patients with type 2 diabetes have an increased risk of cardiovascular events, which can...

Cost-Effectiveness of Statins for Primary Prevention in Patients Newly Diagnosed with Type 2 Diabetes in The Netherlands

de Vries, Folgerdiena M.
Denig, Petra
Visser, Sipke T.
Hak, Eelko
Postma, Maarten J.

March 2014

AbstractBackgroundStatins are lipid-lowering drugs that reduce the risk of cardiovascular events in ...

[Atorvastatin in primary prevention]. [Birincil korunmada atorvastatin.]

Kültürsay H.

January 2009

PubMed ID: 19404046Statins are one of the most widely used drugs in medical treatment and have been ...

Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

Arca, Marcello

January 2007

Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and se...

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Colhoun, H
Betteridge, D
Durrington, P
Hitman, G
Neil, H
Livingstone, S
Thomason, M
Mackness, M
Charlton-Menys, V
Fuller, J

January 2004

BACKGROUND: Type 2 diabetes is associated with a substantially increased risk of cardiovascular dise...

Statins for cardiovascular prevention according to different strategies: a cost analysis

Ito, Marcia K
Nanchen, David
Rodondi, Nicolas
Paccaud, Fred
Waeber, Gérard
Vollenweider, Peter
Marques-Vidal, Pedro

January 2011

Several studies have shown that treatment with HMG-CoA reductase inhibitors (statins) can reduce cor...

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).

Knopp, Robert H
d'Emden, Michael
Smilde, Johan G
Pocock, Stuart J

January 2006

OBJECTIVE: Cardiovascular disease (CVD) risk is increased in type 2 diabetes. The purpose of this st...

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes:results from the Collaborative Atorvastatin Diabetes Study (CARDS)

Raikou, M
McGuire, A
Colhoun, H M
Betteridge, D J
Durrington, P N
Hitman, G A
Neil, H A W
Livingstone, S J
Charlton-Menys, V
Fuller, J H

January 2007

We estimated the cost-effectiveness of atorvastatin treatment in the primary prevention of cardiovas...

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).

Raikou, M
McGuire, A
Colhoun, HM
Betteridge, DJ
Durrington, PN
Hitman, GA
Neil, HA
Livingstone, SJ
Charlton-Menys, V
Fuller, JH

April 2007

AIMS/HYPOTHESIS: We estimated the cost-effectiveness of atorvastatin treatment in the primary preven...

Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: A French adaptation of CARDS

Lafuma, Antoine
Colin, Xavier
Solesse, Anne

May 2008

SummaryIntroductionWe estimated the cost-effectiveness of atorvastatin in the primary prevention of ...

Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative Atorvastatin diabetes study in the Belgian population

Annemans, Lieven
Marbaix, S
Webb, K
Van Gaal, Luc
Scheen, A

January 2010

Background and Objective: Patients with type 2 diabetes mellitus have a high risk of developing card...

Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.

Annemans, L.
Marbaix, S.
Webb, K.
Van Gaal, L.
Scheen, André

January 2010

BACKGROUND AND OBJECTIVE: Patients with type 2 diabetes mellitus have a high risk of developing card...

CANADIAN JOURNAL OF DIABETES. 2009;33(4):363-374. COST-EFFECTIVENESS OF ATORVASTATIN IN DIABETES | 363

August 2015

OBJECTIvE: To assess the clinical and economic benefits of atorvastatin for Canadian patients with t...

Economic evaluation of the CARDS study

Lorenzo G. Mantovani
Simona de Portu
Enrica Menditto

September 2006

Introduction: cardiovascular diseases (CVD) are the major component of premature mortality, generate...

Cost-effectiveness of statins for primary prevention in newly diagnosed type 2 diabetes patients: An illustration for The Netherlands

De Vries, Folgerdiena M.
Denig, Petra
Visser, Sipke T.
Hak, Eelko
Postma, Maarten J.

October 2013

Background: Patients with type 2 diabetes have an increased risk of cardiovascular events, which can...

Cost-effectiveness of statins for primary prevention in newly diagnosed type 2 diabetes patients:An illustration for The Netherlands

De Vries, Folgerdiena M.
Denig, Petra
Visser, Sipke T.
Hak, Eelko
Postma, Maarten J.

October 2013

Background: Patients with type 2 diabetes have an increased risk of cardiovascular events, which can...

Cost-Effectiveness of Statins for Primary Prevention in Patients Newly Diagnosed with Type 2 Diabetes in The Netherlands

de Vries, Folgerdiena M.
Denig, Petra
Visser, Sipke T.
Hak, Eelko
Postma, Maarten J.

March 2014

AbstractBackgroundStatins are lipid-lowering drugs that reduce the risk of cardiovascular events in ...

[Atorvastatin in primary prevention]. [Birincil korunmada atorvastatin.]

Kültürsay H.

January 2009

PubMed ID: 19404046Statins are one of the most widely used drugs in medical treatment and have been ...

Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

Arca, Marcello

January 2007

Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and se...

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Colhoun, H
Betteridge, D
Durrington, P
Hitman, G
Neil, H
Livingstone, S
Thomason, M
Mackness, M
Charlton-Menys, V
Fuller, J

January 2004

BACKGROUND: Type 2 diabetes is associated with a substantially increased risk of cardiovascular dise...

Statins for cardiovascular prevention according to different strategies: a cost analysis

Ito, Marcia K
Nanchen, David
Rodondi, Nicolas
Paccaud, Fred
Waeber, Gérard
Vollenweider, Peter
Marques-Vidal, Pedro

January 2011

Several studies have shown that treatment with HMG-CoA reductase inhibitors (statins) can reduce cor...

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).

Knopp, Robert H
d'Emden, Michael
Smilde, Johan G
Pocock, Stuart J

January 2006

OBJECTIVE: Cardiovascular disease (CVD) risk is increased in type 2 diabetes. The purpose of this st...

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes:results from the Collaborative Atorvastatin Diabetes Study (CARDS)

Abstract

Extracted data

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes:results from the Collaborative Atorvastatin Diabetes Study (CARDS)

Abstract

Extracted data

Related items

Related items